Related Experiment Video

Updated: Jun 11, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure

Andreas Schäfer1, Daniela Fraccarollo, Lennart Werner

  • 1Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Bayerische Julius-Maximilians-Universität Würzburg, Germany. a.schaefer@medizin.uni-wuerzburg.de

Pharmacological Research
|July 6, 2010
PubMed

Insights

Activating soluble guanylyl cyclase (sGC) with ataciguat improved blood vessel function and reduced platelet activation in rats with heart failure. This suggests a potential therapeutic strategy for cardiovascular conditions.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Physiology

Background:

  • Congestive heart failure (CHF) is characterized by endothelial dysfunction and platelet activation.
  • Impaired nitric oxide (NO) signaling contributes to these cardiovascular issues in CHF.

Purpose of the Study:

  • To investigate the effects of chronic soluble guanylyl cyclase (sGC) activation on vascular function and platelet activation in experimental CHF.
  • To assess whether the sGC activator ataciguat could beneficially modulate these parameters.

Main Methods:

  • Myocardial infarction was induced in rats to create a CHF model.
  • Animals were treated with either placebo or the sGC activator ataciguat.
  • Hemodynamics, vasomotor function, NO bioavailability (VASP phosphorylation), and platelet activation (P-selectin) were assessed.

Main Results:

  • Ataciguat normalized impaired endothelium-dependent vasorelaxation and vascular sensitivity to NO in CHF rats.
  • Treatment with ataciguat restored NO bioavailability, indicated by normalized VASP phosphorylation in platelets.
  • Ataciguat significantly reduced platelet activation in CHF rats.

Conclusions:

  • Chronic activation of sGC with ataciguat improved vasomotor function in experimental CHF.
  • sGC activation effectively reduced platelet activation in this CHF model.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...